六君子汤加减辅助晚期非小细胞肺癌化疗的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 六君子汤加减辅助晚期非小细胞肺癌化疗的临床观察
TITLE:
摘要: 目的:观察六君子汤加减辅助晚期非小细胞肺癌化疗的疗效和安全性。方法:118例晚期非小细胞肺癌患者随机分为观察组(59例)和对照组(59例)。两组患者于化疗前12、6 h给予醋酸地塞米松片15 mg,口服,化疗前30 min给予盐酸苯海拉明注射液20 mg,肌内注射,同时行常规抑酸、保肝、止吐、水化、利尿等治疗。在此基础上,对照组患者给予紫杉醇注射液175 mg/m2,静脉滴注,3 h内滴完,d1,30 min后给予注射用顺铂25 mg/m2,静脉滴注2 h,d1-3;观察组患者在对照组治疗的基础上给予六君子汤加减,水煎至200 mL,每日1剂,早晚分服。两组均以21 d为1个周期,共治疗4个周期。观察两组患者的近期疗效,化疗前后T淋巴细胞亚群水平、肿瘤标志物水平[癌胚抗原(CEA)、鳞状上皮细胞癌抗原(SCC-Ag)和细胞角蛋白19的可溶性片段(CYFRS21-1)]及毒副反应发生情况。结果:观察组患者近期总有效率(49.15%)显著高于对照组(32.20%),血小板降低、白细胞降低、肝功能异常、消化道反应、外周神经损伤发生率均显著低于对照组,差异均有统计学意义(P<0.05)。化疗后,观察组患者CD4+、CD4+/CD8+均显著高于同组化疗前,CD8+显著低于同组化疗前,对照组患者CD4+、CD4+/CD8+均显著低于同组化疗前,CD8+显著高于同组化疗前,且观察组CD4+、CD4+/CD8+显著高于对照组,CD8+显著低于对照组;两组患者肿瘤标志物水平均显著低于同组化疗前,且观察组显著低于对照组,差异均有统计学意义(P<0.05)。结论:在常规治疗的基础上,六君子汤加减用于晚期非小细胞肺癌的疗效显著,可改善患者免疫功能,减轻毒副反应。
ABSTRACT: OBJECTIVE: To observe the therapeutic efficacy and safety of modified Liujunzi decoction in adjuvant chemotherapy for advanced non-small cell lung cancer (NSCLC). METHODS: A total of 118 patients with advanced NSCLC were randomly divided into observation group and control group, with 59 cases in each group. Both groups were given Dexamethasone acetate tablets 15 mg orally 12, 6 h before chemotherapy, Diphenhydramine hydrochloride injection 20 mg intramuscularly 30 min before chemotherapy, and also given routine treatment as acid suppression, liver protection, antiemetic, hydration and dieresis. Control group was additionally given Paclitaxel injection 175 mg/m2 intravenously within 3 h, d1, and 30 min later given Cisplatin for injection 25 mg/m2 intreavenously for 2 h, d1-3. Observation group was additionally given modified Liujunzi decoction, decocted to 200 mL, one dose a day, morning and night, on the basis of control group. A treatment course of 2 groups lasted for 21 d, and both received 4 courses. The short-term efficacies of 2 groups were observed. The levels of T lymphocyte subset and tumor marker (CEA, SCC-Ag, CYFRS21-1), the occurrence of toxic reaction were observed before and after chemotherapy. RESULTS: Total response rate of observation group (49.15%) was significantly higher than that of control group(32.20%); the incidence of thrombocytopenia, leucopenia, abnormal liver function, digestive tract reaction and peripheral nerve injury was significantly lower than control group, with statistical significance (P<0.05). After treatment, CD4+ and CD4+/CD8+ of observation group were significantly higher than before chemotherapy, while CD8+ was significantly lower than before chemotherapy; CD4+ and CD4+/CD8+ of control group were significantly lower than before chemotherapy, while CD8+ was significantly higher than before chemotherapy; CD4+ and CD4+/CD8+ of observation group were significantly higher than those control group, while CD8+ was significantly lower than control group; The levels of tumor markers in 2 groups were significantly lower than before chemotherapy, and the observation group was significantly lower than the control group, with statistical significance (P<0.05). CONCLUSIONS: Based on routine treatment, modified Liujunzi decoction shows significant therapeutic efficacy for NSCLC, improves immune function and relieve toxic reaction.
期刊: 2017年第28卷第36期
作者: 李德辉,孙春霞,范焕芳
AUTHORS: LI Dehui,SUN Chunxia,FAN Huanfang
关键字: 非小细胞肺癌;紫杉醇;顺铂;六君子汤;疗效;安全性
KEYWORDS: Non-small cell lung cancer; Paclitaxel; Cisplatin; Liujunzi decoction; Therapeutic efficacy; Safety
阅读数: 116 次
本月下载数: 1 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!